New Antibiotic Targets Drug-Resistant Bacteria While Preserving Gut Health

Lolamicin shows promise in treating gram-negative infections without disrupting beneficial gut microbes, offering a potential breakthrough in antibiotic therapy.

Lolamicin effectively treats drug-resistant pneumonia and sepsis in mice.
The antibiotic spares beneficial gut bacteria, preventing secondary infections like C. difficile.
It shows efficacy against over 130 multidrug-resistant bacterial strains in cell culture.
Current antibiotics often harm beneficial gut bacteria, leading to further health issues.
Further research is needed to test lolamicin against more strains and assess resistance development.